- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04452305
Spermatogonial Stem Cell (SSC) Transplant and Testicular Tissue Grafting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Azoospermia (no sperm in ejaculated semen) impacts 1% of men in the general population and 15% of infertile men, which translates to 645,000 males between the ages of 20 and 50 (prime reproductive years) in the United States. Spermatogenesis arises from a population of spermatogonial stem cells in the testes that maintain continuous sperm production throughout a man's post-pubertal life. Diseases or medical treatments that compromise the stem cell pool and/or prevent the stem cells from differentiating can cause infertility. Adult men have the option to cryopreserve a semen sample prior to therapy but this is not an option for prepubertal patients who are not yet producing sperm. This study will test the safety and feasibility of two approaches to restore sperm production using previously cryopreserved testicular tissues, which contain spermatogonial stem cells.
The first approach is autologous transplantation of testicular cells, including spermatogonial stem cells, into the testis using ultrasound-guided rete testis injection. The second approach is autologous grafting of intact pieces of testicular tissue under the skin in the scrotum.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rachel Neelley
- Phone Number: 1 412-641-7475
- Email: fertilitypreservation@upmc.edu
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- Magee-Womens Hospital
-
Contact:
- Rachel Neelley
- Phone Number: 1 412-641-7475
- Email: fertilitypreservation@upmc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male participant at least in Tanner stage 3
- Previously cryopreserved and stored testicular tissue/cells (frozen due to an infertility-risking diagnosis or treatment such as chemotherapy or radiation) available for autologous transplantation and grafting
- Healthy enough to undergo anesthesia
- Written clearance for the procedure from the patient's hematologist or oncologist to confirm the patient has finished treatment for primary condition and are clear to undergo autologous stem cell transplant
Exclusion Criteria:
- Participants considered to be high risk for surgical complications
- Participants with a history of leukemia, lymphoma or testicular cancer or a cancer that likely involved testicles at the time of testicular tissue collection
- Diagnosed with psychological, psychiatric, or other conditions which prevent giving fully informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Spermatogonial Stem Cell Transplant & Testicular Tissue Graft
Stem cell transplantation Testicular tissue grafting
|
Spermatogonial stem cell transplant and testicular tissue grafting is performed to produce sperm.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with return of spermatogenesis
Time Frame: 3 months-1year
|
Rate of participants where sperm was found in semen analysis or testicular tissue analysis
|
3 months-1year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with cancer recurrence
Time Frame: 5 years
|
Rate of participants diagnosed with cancer recurrence
|
5 years
|
Number of participants with surgical complications of SSC transplantation and testicular tissue grafting
Time Frame: 3 months
|
Rate of infection, hospital readmission, re-operation occurs
|
3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Kyle E Orwig, PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY20030111
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
Clinical Trials on Spermatogonial Stem Cell Transplant and Testicular Tissue Grafting
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityAvailableMalignant Neoplasm | Hematopoietic Cell Transplantation Recipient | Benign Neoplasm | Bone Marrow Transplantation RecipientUnited States
-
University of UtahTerminatedHigh Risk Hematologic MalignanciesUnited States
-
St. Jude Children's Research HospitalCompletedAnemia, Aplastic | Diamond-Blackfan Anemia | Amegakaryocytic Thrombocytopenia | Kostmann SyndromeUnited States
-
University College, LondonBloodwiseActive, not recruitingHodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Myelodysplastic Syndrome | Acute Myeloid Leukaemia | Chronic Lymphocytic Leukaemia | Acute Lymphoblastic Leukaemia | Chronic Myeloid Leukaemia | Acquired Bone Marrow Failure Syndromes | Other Haematological Malignancies; Unrelated HSCT IndicatedUnited Kingdom
-
Richard Burt, MDTerminated
-
St. Jude Children's Research HospitalCompletedAcute Myeloid Leukemia | Leukemia | Hodgkin's Lymphoma | Juvenile Myelomonocytic Leukemia | Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Paroxysmal Nocturnal HemoglobinuriaUnited States
-
Duke UniversityTerminated
-
Masonic Cancer Center, University of MinnesotaRecruitingMucopolysaccharidosis Type I | Hematopoietic Cell TransplantationUnited States
-
Northwestern UniversityCompletedSYSTEMIC SCLERODERMAUnited States
-
David Rizzieri, MDCompletedLeukemia | Myelodysplasia | Myeloma | Non Hodgkin's Lymphoma | Hodgkin's DiseaseUnited States